Source - SMW
MaxCyte has posted its financial results for the six months ended 30 June 2016. The highlights are:

- Revenues of $5.5 million for the six months ended 30 June 2016, a 30.3% increase over $4.2 million for the same period of 2015

- Gross margins remained stable over the six months ended 30 June 2016 and 2015 at 89.5% and 89.0%, respectively

- Operating expenses increased to $5.9 million compared to $4.3 million for the same period of 2015

- CARMA investment totalled $0.5 million for the six months ended 30 June 2016, compared to $0.1 million for the same period of 2015

- Net loss before CARMA expenses was $0.8 million for the six months ended 30 June 2016, (including $0.3 million in expenses newly arising from the Company's position as a public company), compared to net loss before CARMA expenses of $0.9 million for the same period of 2015

- Deferred revenues increased from $2.0 million at the end of 2015 to $2.6 million at 30 June 2016 due principally to growth in technology licenses

- Cash balance of $12.2 million at 30 June 2016, compared to $2.4 million at the end of 2015

- Completed restructuring of Company's existing $5.1 million debt facility in June 2016 to extend it by approximately two years, increasing the interest-only period to July 2018 and maturity to June 2021, providing additional financial flexibility

- Successful Initial Public Offering on the AIM market of the London Stock Exchange on 29 March 2016 ("IPO"), raising £10.0 million (before expenses) for the Company.




At 9:45am: (LON:MXCT) Maxcyte Inc share price was 0p at 84.5p



Related Charts

Maxcyte Inc (MXCT)

+1.00p (+0.74%)
delayed 18:15PM